S-sulfocysteine/NMDA receptor–dependent signaling underlies neurodegeneration in molybdenum cofactor deficiency
Authors:
- Avadh KumarAKAvadh Kumar
- Borislav DejanovicBDBorislav Dejanovic
- Florian HetschFHFlorian Hetsch
- Marcus SemtnerMSMarcus Semtner
- Debora FuscaDFDebora Fusca
- Sita ArjuneSASita Arjune
- Aline WinkelmannAWAline Winkelmann
- Scott AytonSAScott Ayton
- Ashley I. BushAshley I. Bush
- Peter KloppenburgPKPeter Kloppenburg
- Jochen C. MeierJMJochen C. Meier
Open Access
- 23 October 2017
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 127 (12) , 4365-4378
Abstract
Molybdenum cofactor deficiency (MoCD) is an autosomal recessive inborn error of metabolism characterized by neurodegeneration and death in early childhood. The rapid and progressive neurodegeneration in MoCD presents a major clinical challenge and may relate to the poor understanding of the molecular mechanisms involved. Recently, we reported that treating patients with cyclic pyranopterin monophosphate (cPMP) is a successful therapy for a subset of infants with MoCD and prevents irreversible brain damage. Here, we studied S-sulfocysteine (SSC), a structural analog of glutamate that accumulates in the plasma and urine of patients with MoCD, and demonstrated that it acts as an N-methyl D-aspartate receptor (NMDA-R) agonist, leading to calcium influx and downstream cell signaling events and neurotoxicity. SSC treatment activated the protease calpain, and calpain-dependent degradation of the inhibitory synaptic protein gephyrin subsequently exacerbated SSC-mediated excitotoxicity and promoted loss of GABAergic synapses. Pharmacological blockade of NMDA-R, calcium influx, or calpain activity abolished SSC and glutamate neurotoxicity in primary murine neurons. Finally, the NMDA-R antagonist memantine was protective against the manifestation of symptoms in a tungstate-induced MoCD mouse model. These findings demonstrate that SSC drives excitotoxic neurodegeneration in MoCD and introduce NMDA-R antagonists as potential therapeutics for this fatal disease.Keywords
Funding Information
- Center for Molecular Medicine Cologne (CMMC-D5 Schwarz)
This publication has 50 references indexed in Scilit:
- Metal insertion into the molybdenum cofactor: product–substrate channelling demonstrates the functional origin of domain fusion in gephyrinBiochemical Journal, 2013
- Impaired Sulfate Metabolism and Epigenetics: Is There a Link in Autism?Entropy, 2012
- Molybdenum Cofactor Deficiency: A New HPLC Method for Fast Quantification of S-Sulfocysteine in Urine and Serum2011
- Irregular RNA splicing curtails postsynaptic gephyrin in the cornu ammonis of patients with epilepsyBrain, 2010
- Physiological and Pathological Actions of Calpains in Glutamatergic NeuronsScience Signaling, 2008
- Heavy neurofilament accumulation and α-spectrin degradation accompany cerebellar white matter functional deficits following forebrain fluid percussion injuryExperimental Neurology, 2007
- Molybdenum Cofactor Deficiency: Report of Three Cases Presenting as Hypoxic Ischemic EncephalopathyJournal of Child Neurology, 2001
- Glutamate‐induced mitochondrial depolarisation and perturbation of calcium homeostasis in cultured rat hippocampal neuronesThe Journal of Physiology, 1999
- Dextrometorphan in molybdenum cofactor deficiencyEuropean Journal of Pediatrics, 1996
- Combined deficiency of xanthine oxidase and sulphite oxidase: A defect of molybdenum metabolism or transport?Journal of Inherited Metabolic Disease, 1978